ASN: Model Predicts Benefit of SGLT2 Inhibitors for Adults With T1DM
Steno Type 1 Risk Engine predicts substantial reduction in risks for CVD, ESKD with SGLT2i as adjunct therapy for type 1 diabetes
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.